Stifel Initiates Coverage On Roivant Sciences with Buy Rating, Announces Price Target of $51

Stifel analyst Alex Thompson has initiated coverage on Roivant Sciences (NASDAQ: ROIV) with a Buy rating. The analyst has set a price target of $51 for the company's stock.